TL;DR: The Centers for Medicare & Medicaid Services modified NCD 6, its cellular therapy coverage policy, with an effective date of January 9, 2026. Cellular therapy remains a non-covered service under Medicare — and this update reinforces that any claim you submit for it will be denied.
This policy governs Medicare's position on cellular therapy, which CMS defines as injecting humans with foreign proteins such as placenta or lung tissue from unborn lambs. NCD 6 in the CMS system classifies these services as not reasonable and necessary under Section 1862(a)(1) of the Social Security Act. The policy lists no specific CPT or HCPCS codes — which creates its own billing challenge, covered below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cellular Therapy — NCD 6 |
| Policy Code | NCD 6 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | Medium — low claim volume, but high denial risk for any billing attempt |
| Specialties Affected | Integrative medicine, internal medicine, oncology, any specialty offering cellular or biological therapies |
| Key Action | Flag all cellular therapy services in your charge capture as non-covered under Medicare before January 9, 2026 |
CMS Cellular Therapy Coverage Criteria and Medical Necessity Requirements 2026
NCD 6 is the National Coverage Determination governing Medicare coverage of cellular therapy. CMS has held this position for years: cellular therapy does not meet the medical necessity standard under Medicare.
The policy language is blunt. CMS describes cellular therapy as "without scientific or statistical evidence to document its therapeutic efficacy." The agency goes further, calling it "a potentially dangerous practice." That's not ambiguous language — it's a categorical exclusion.
Under Section 1862(a)(1) of the Social Security Act, Medicare only covers items and services that are reasonable and necessary for the diagnosis or treatment of illness or injury. CMS has determined that cellular therapy fails that standard. No exceptions, no clinical carve-outs.
Whether your patient asks about this, whether a provider believes in its efficacy, or whether another payer covers it — none of that changes Medicare's position. The CMS cellular therapy coverage policy is a hard stop.
If your practice operates in a state where a Medicare Administrative Contractor (MAC) has issued a local coverage determination (LCD) that touches on biological or cellular therapies, check whether that LCD conflicts with or supplements NCD 6. National coverage determinations take precedence over LCDs, but your MAC may have related policies that affect your documentation or billing approach for adjacent services.
CMS Cellular Therapy Exclusions and Non-Covered Indications
The exclusion here is total. CMS does not cover cellular therapy for any indication.
This is not a situation where prior authorization might unlock coverage. Prior authorization doesn't apply when a service is categorically excluded from coverage — there's nothing to authorize. Submitting a prior auth request for cellular therapy under Medicare is a wasted step.
The policy also doesn't distinguish between different delivery methods, tissue sources, or clinical contexts. Cellular therapy is cellular therapy under this NCD. Injecting patients with animal-derived foreign proteins — regardless of the claimed therapeutic rationale — falls under this blanket exclusion.
The real risk for billing teams isn't confusion about criteria. The risk is a provider who offers these services, a patient who wants Medicare to pay, and a billing team that doesn't know the national policy clearly enough to push back before the claim goes out.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Cellular therapy (injection of foreign proteins, e.g., animal-derived placenta or lung tissue) | Not Covered | No specific codes listed in NCD 6 | Excluded under Section 1862(a)(1); not reasonable and necessary |
| Any cellular therapy indication, regardless of clinical context | Not Covered | No specific codes listed | No exceptions defined in the policy |
CMS Cellular Therapy Billing Guidelines and Action Items 2026
The January 9, 2026 effective date is your line in the sand. Here's what to do before and after it.
| # | Action Item |
|---|---|
| 1 | Audit your charge master and encounter forms for any cellular therapy services before January 9, 2026. Flag these as Medicare non-covered. If your EHR or billing system has a non-covered service designation, apply it now. |
| 2 | Train your front desk and financial counseling staff. If a Medicare patient asks whether cellular therapy is covered, the answer is no — full stop. Your staff should be able to explain this without escalating every conversation to a biller. |
| 3 | Issue an Advance Beneficiary Notice of Noncoverage (ABN) if your provider plans to offer cellular therapy services to Medicare patients. An ABN shifts financial liability to the patient when Medicare won't cover a service. Without it, you can't bill the patient. This is where your reimbursement strategy for these services has to start — not after the claim denies. |
| 4 | Do not submit cellular therapy claims to Medicare expecting payment. A claim denial is the guaranteed outcome. Repeated denials for non-covered services can trigger payer audits and, in some cases, flag your billing patterns for review. Don't test this policy. |
| 5 | Review any claims submitted in the 90 days before January 9, 2026 for cellular therapy services. If your practice billed these services to Medicare and received payment, talk to your compliance officer. Depending on what was submitted and paid, you may have a repayment obligation. This is not a scenario to handle without guidance. |
| 6 | Check your payer mix beyond Medicare. This NCD applies to Medicare. Commercial payers may have different positions on cellular therapy billing. Verify coverage separately with Cigna Healthcare, UnitedHealthcare, and any other commercial payers in your mix before assuming the Medicare exclusion applies universally. |
| 7 | If you're unsure how this policy interacts with other biological therapy services your practice bills, loop in your compliance officer before the effective date. Some services that sound adjacent — like certain stem cell therapies or biologics — have entirely different coverage frameworks. Don't assume NCD 6 covers or excludes them without checking. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cellular Therapy Under NCD 6
Covered CPT Codes
There are no covered CPT or HCPCS codes under NCD 6. CMS does not cover cellular therapy under any code.
Not Covered / Experimental Codes
The policy does not list specific CPT, HCPCS, or ICD-10 codes. This is unusual for an NCD and creates a real-world billing problem: there's no clean code-level flag you can apply to automatically catch these claims.
This is not an oversight you can work around by assuming the policy is narrowly scoped. CMS's language covers the category of service — not specific procedure codes. Your charge capture controls need to catch these services at the clinical description level, not the code level.
What This Means for Your Denial Management
When a policy has no associated codes, your standard code-based claim scrubbing won't catch a cellular therapy claim before it goes out. You need a manual flag, a provider education protocol, or a workflow step that identifies these services before they hit the clearinghouse. This is where cellular therapy billing breaks down in practice — not because the policy is complicated, but because there's no CPT or HCPCS guardrail to catch a mistake automatically.
If your practice has ever billed something for these services — whether a generic injection code, an unlisted procedure code, or anything else — and Medicare paid it, that's a compliance exposure. Talk to your compliance officer.
Why This Policy Revision Matters Even Though the Coverage Position Hasn't Changed
Here's the honest take: the coverage position in NCD 6 isn't new. CMS has excluded cellular therapy from Medicare coverage for a long time. So why does a modification to this policy in 2026 matter to your billing team?
Two reasons.
First, a policy modification — even one that doesn't change the coverage outcome — resets the clock on regulatory awareness. If your practice has grown, changed specialties, added providers, or shifted its service mix since the last time anyone reviewed NCD 6, this update is your prompt to re-verify your internal controls. Policies don't stay relevant by accident.
Second, the framing of this policy is worth understanding. CMS explicitly calls cellular therapy dangerous. That's stronger language than "experimental" or "investigational." It signals that this isn't a coverage gap waiting to be filled with new clinical evidence. This is a categorical exclusion, and the agency isn't signaling any openness to revisiting it.
For billing teams, that means you're not waiting for a coverage determination update that unlocks reimbursement. You're managing a permanent non-covered service. Your job is to make sure providers understand that, patients are informed before services are rendered, and ABNs are in place when they need to be.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.